Biology subjects

Rivera, I. S.

Publications and source records attributed to Rivera, I. S..

3 recordsLinked to original sources

bioRxiv2026

An MLL-Independent Function of Menin Promotes Resistance to MAPK-Targeted Therapy

BRAF mutant colorectal cancer (CRC) remains difficult to treat despite the clinical use of combined BRAF and EGFR inhibition, highlighting a need to define tumour-intrinsic mechanisms that limit therapeutic response. Here, using genome-wide CRISPR-Cas9 screening in BRAF-mutant CRC cells, we identify MEN1, encoding the chromatin-associated protein Menin, as a selective determinant of sensitivity to combined encorafenib and cetuximab (EC). MEN1 loss markedly enhanced EC-mediated inhibition of cell proliferation and ERK activity while having comparatively little effect in untreated cells, and re-expression of Menin restored resistance. Transcriptomic and chromatin profiling revealed that Menin supports the transcriptional response associated with MAPK signalling. Menin occupied promoters of MAPK/BRAF-responsive genes and EC treatment caused widespread displacement of Menin from chromatin. Phosphoproteomic analysis demonstrated extensive remodelling of MAPK signalling following EC treatment, whereas proximity proteomics showed that the Menin-associated protein complexes remained largely intact despite loss of Menin chromatin occupancy. Importantly, MLL1 loss did not reproduce the sensitising effect of MEN1 deletion, and pharmacological Menin inhibition with revumenib failed to phenocopy either genetic MEN1 loss or acute Menin degradation, indicating that this phenotype is independent of Menin-MLL activity. Together, these findings identify a previously unrecognised, MLL-independent role for Menin in buffering the response of BRAF-mutant CRC cells to MAPK pathway inhibition and suggest targeting Menin, rather than disruption of its interaction with MLL, may provide a strategy for enhancing the response to BRAF-targeted therapy for CRC.

cancer biology↗

bioRxiv2026

INTS12 Bridges Integrator and NELF to Prevent the Release of Non-processive RNA Polymerase II Complexes

Promoter-proximal RNA Polymerase II (RNAPII) pausing and the processivity are controlled by distinct modules of the Integrator complex, which together fine-tune transcription and protect against the accumulation of defective RNAPII complexes. Compromised activity of individual Integrator modules has been linked to human disease including cancer and developmental disorders, caused by defective transcription of protein-coding or small-nuclear RNAs. Despite extensive characterisation of the Integrator complex both genetically and structurally, the role of smallest member of the complex, INTS12, has remained enigmatic. Here, we uncover that INTS12 loss acts to stabilise the association between NELF and Integrator via its PHD domain and N-terminus, respectively, thus safeguarding against the release of defective RNAPII complexes. Acute degradation of INTS12 results in the selective dissociation of Integrator from the NELF-RNAPII complex which subsequently convert to their canonical paused form from which they can be released by CDK9. In the absence of INTS12 excess release of defective RNAPII via P-TEFb/SEC, loss of the ARMC5 salvage pathway and deletion of the catalytic and core Integrator subunits is toxic to cells. These findings demonstrate that there is interconversion between canonical paused RNAPII and paused-Integrator, and highlight the critical interplay between these processes and P-TEFb mediated pause-release to ensure that only transcription competent complexes are released into elongation. O_LIINTS12 degradation confers CDK9 inhibitor resistance and triggers cellular stress through a phosphatase module-independent mechanism. C_LIO_LIINTS12 stabilizes the Integrator-NELF complex through its N-terminus and PHD domain. C_LIO_LIAcute INTS12 degradation promotes aberrant release of promoter-proximal RNA polymerase II complexes. C_LIO_LIRNA polymerase II complexes released upon INTS12 loss exhibit defective elongation and reduced processivity. C_LIO_LIINTS12 loss removes Integrator from RNAPII resulting in aberrant paused-state from which it can be released by CDK9. C_LIO_LIExcess CDK9 activity and ARMC5 loss are synthetically lethal with INTS12 deficiency. C_LI

molecular biology↗

bioRxiv2022

Redefining normal breast cell populations using long noncoding RNAs

Single-cell RNAseq has allowed unprecedented insight into gene expression across different cell populations in normal tissue and disease states. However, almost all studies rely on annotated gene sets to capture gene expression levels and sequencing reads that do not align to known genes are discarded. Here, we discover thousands of long noncoding RNAs (lncRNAs) expressed in human mammary epithelial cells and analyze their expression in individual cells of the normal breast. We show that lncRNA expression alone can discriminate between luminal and basal cell types and define subpopulations of both compartments. Clustering cells based on lncRNA expression identified additional basal subpopulations, compared to clustering based on annotated gene expression, suggesting that lncRNAs can provide an additional layer of information to better distinguish breast cell subpopulations. In contrast, these breast-specific lncRNAs poorly distinguish brain cell populations, highlighting the need to annotate tissue-specific lncRNAs prior to expression analyses. We also identified a panel of 100 breast lncRNAs that could discern breast cancer subtypes better than protein-coding markers. Overall, our results suggest that lncRNAs are an unexplored resource for new biomarker and therapeutic target discovery in the normal breast and breast cancer subtypes.

cell biology↗